Department of Pharmacology, Faculty of Pharmaceutical Sciences, Chiba Institute of Science, Choshi, Chiba, Japan.
J Pharmacol Sci. 2010;113(3):285-8. doi: 10.1254/jphs.10118sc. Epub 2010 Jul 1.
Endoplasmic reticulum-associated degradation (ERAD) is a quality control mechanism in which unfolded proteins are retro-translocated to the cytosol for degradation. Our recent study showed that suppression of expression of ubiquitin ligase HRD1, which is involved in ERAD, caused amyloid precursor protein (APP) accumulation and amyloid-beta (Abeta) production. Furthermore, HRD1 protein levels were significantly lower in the cerebral cortex of Alzheimer's disease (AD) patients. To assess whether HRD1 is involved in AD pathology, we analyzed the relationship between HRD1 protein levels and Abeta production. We found that the HRD1 level was negatively correlated with the Abeta level, suggesting the possible involvement of HRD1 in Abeta generation.
内质网相关降解(ERAD)是一种质量控制机制,其中未折叠的蛋白质被逆向转运到细胞质中进行降解。我们最近的研究表明,抑制参与 ERAD 的泛素连接酶 HRD1 的表达会导致淀粉样前体蛋白(APP)积累和淀粉样β(Abeta)产生。此外,AD 患者大脑皮层中的 HRD1 蛋白水平显著降低。为了评估 HRD1 是否参与 AD 病理学,我们分析了 HRD1 蛋白水平与 Abeta 产生之间的关系。我们发现 HRD1 水平与 Abeta 水平呈负相关,这表明 HRD1 可能参与了 Abeta 的生成。